Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Glam Derma
WARNING LETTER
•Glam Derma•November 1, 2025

Glam Derma – FDA Warning Letter, Nov 1, 2025

Record Details

The FDA issued a Warning Letter to Glam Derma on November 3, 2025, after reviewing its website, www.glamderma.com. The letter identifies significant violations related to introducing unapproved and misbranded injectable botulinum toxin drug products, such as “NABOTA 100 Type A” and “Nabota 100,” into U.S. interstate commerce.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), these products are considered unapproved new drugs because they lack required FDA approval for safety and effectiveness (sections 301(d) and 505(a)). They are also misbranded (sections 301(a) and 502(f)(1)) as they are prescription drugs that cannot be safely used by laypersons without professional supervision, thus lacking adequate directions for use. The FDA emphasizes the serious health risks associated with unapproved injectable drugs, including potential contamination, counterfeiting, inconsistent active ingredients, and life-threatening complications like sepsis or systemic toxin spread.

Glam Derma is required to immediately cease selling all unapproved and misbranded drugs to U.S. consumers. The company must respond in writing within 15 working days, detailing the specific corrective actions taken to address the violations and prevent their recurrence. Failure to comply may lead to further legal action, including product seizure or injunction.

Company
Glam Derma
Inspection date
November 1, 2025
Product type
Drugs
Office
Office of Drug Security, Integrity, and Response
Person
  • Sangeeta V. Chatterjee
View Company Profile

ID · e17b61f2-a89e-47c9-ada5-9d050215fc79

Violation Codes10
FD&C Act 301(a)FD&C Act 301(d)FD&C Act 503(b)FD&C Act 505(a)21.U.S.C. 331(a)21 U.S.C. 331(d)21 U.S.C. 353(b)21.U.S.C. 355(a)FD&C Act 201(g)21 U.S.C. 321(g)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Glam Derma
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.